Healthcare Services Group, Inc.
HCSGHealthcare Services Group, Inc.'s three tracks disagree. Price, valuation and the earnings engine each tell a different story — the next quarter or two settles it.
Biggest watch item: the price is not yet in a confirmed uptrend — timing risk, not thesis risk.
The price is between stages. Underneath, the last four quarters read improving — profit +50.0% year on year, and 150% of the last 3 years' profit arrived as cash. What settles it: the next one or two quarters of delivery.
Price story Before the numbers, the tape. A stock price moves through four repeating seasons: a flat base (stage 1), an advance (2), a top (3), a decline (4). Where the price sits in that cycle frames everything below.
Healthcare Services Group, Inc. trades at $23.1, between stages. That is +13.9% against its own 200-day average. It sits at 79% of a 52-week range of $15 to $25. On relative strength it is currently behind the S&P 500 on a trailing-13-week view (1 week and counting).
Today the stock is between stages. At $23.1 it trades +13.9% versus its 200-day average and sits at 79% of its 52-week range ($15–$25).
Against the market, two honest reads. Cumulative: over the last 1.1 years the stock moved +71% while the S&P 500 moved +24% — ahead of the index over the full window. Recent form: on a trailing-13-week view the stock is currently behind (1 week and counting; last ahead the week of 2026-07-31) — the ribbon below is that same metric, week by week.
What would end the trend, mechanically: two Friday closes in a row below the 200-day line. That is the exit rule — no debates.
Valuation P/E is the price of $1 of annual profit: how many dollars the market pays for each dollar the company earns in a year.
Healthcare Services Group, Inc. trades at 13.4× P/E, against too little history to rank. This places the multiple against the stock’s own record, and says nothing about what the business is worth.
Today's P/E of 13.4× is against too little history to rank. This is a comparison against the stock's own history — not a claim about what it is worth.
Why the multiple sits where it does: over the past year annual EPS moved +52.8% against a +77.1% price move — the price outran earnings, pushing the multiple UP its own range.
Put together: the multiple is unremarkable against its own past, so the story rests on the earnings line underneath it, not the multiple.
Stage: Turning around Every business sits somewhere on a fundamental arc, and this page names the spot before anything else. The last twelve quarters of revenue, profit and EPS growth — plus the return the business earns on its capital — are read as curves: Deteriorating (the curves are falling), Turning around (a trough has just formed and the last few quarters lift off it), Improving (the climb off the trough is sustained), Consistent (steadily positive with healthy returns), Topping out (still high but decelerating from the peak). When the curves genuinely disagree the read is Mixed; too little history is No read. CAGR (compound annual growth rate) is the smooth yearly pace that turns the starting value into the latest one — the fairest way to compare growth across different time spans. Read the columns together: if the 1-year number towers over the 10-year, recent growth is running hotter than the long-run trend. A dash means that window is not held, or the base year was a loss (where a growth rate is not meaningful).
Healthcare Services Group, Inc. reads as turning around on its fundamental arc. Turning around — EPS growth swung from −22.9% at the trough to +71.4%, a 2-quarter improving streak, ROCE lifting at 9.9%. The read is built from 12 quarters across 4 curves, on full evidence.
Why it matters: growth inflections are where re-ratings start — the curves say a turn is forming, so the question becomes whether the next quarters confirm it.
| 1yr | 3yr | 5yr | 10yr | |
|---|---|---|---|---|
| Revenue | +7.0% | +2.9% | — | — |
| Profit | +50.0% | +26.0% | — | — |
| EPS | +52.8% | +20.8% | — | — |
| Stock price | +77.1% | — | — | — |
4-Factor Sector Score
53.2/100 — rank 11 of 30 in Medical Care Facilities · 52% evidence confidence
Healthcare Services Group, Inc. scores 53.2 out of 100 against the 30 companies it is compared with in Medical Care Facilities, ranking 11. Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
The four contributions add to the total exactly: 22.9 + 10.6 + 10.4 + 9.3 = 53.2. This is the SAME number shown on the sector comparison — it is computed once, for the whole peer set, and read here.
What would change it: The read weakens if profit growth turns negative or margin improvement reverses while sector-relative strength deteriorates.
Revenue Revenue is the top line: everything the company billed its customers in the period.
Healthcare Services Group, Inc. reported $0.5 B of revenue in the Mar 26 quarter, +2.2% year on year. That is the 8th straight quarter of year-on-year growth. Over 4 years it has compounded at 2.9% a year. The last full year, FY25, came in at $1.8 B. The last four reported quarters add to $1.9 B.
FY25 revenue came in at $1.8 B (+7.0% on the year), capping 4 years at 2.9% compound. The latest quarter (Mar 26) printed $0.5 B, +2.2% year on year — the 8th consecutive quarter of year-over-year growth.
Pace check: the last four quarters averaged +5.8% growth against the decade's 2.9% — the current year is running faster than its own long-run rate.
Acceleration check: trailing-twelve-month revenue grew +5.7% over the last 4 quarters against +5.3%/yr over the last 8 — stabilising; TTM profit +75.0% vs +32.3%/yr — accelerating.
Operating margin Operating margin is what is left of every $100 of sales after running the business, before interest and tax. It is the cleanest read on pricing power and cost control.
Healthcare Services Group, Inc.'s operating margin is 6.5% in the Mar 26 quarter, +2.1 percentage points against the same quarter a year ago. Across 5 fiscal years the operating margin has ranged 2.7% to 3.7%. The current quarter is running above every full year in that window.
The latest quarter's operating margin is 6.5%, +2.1 pp against the same quarter a year ago. Across 5 fiscal years the operating margin has ranged 2.7%–3.7%.
Why the margin moved: operating margin went +2.1 pp year on year while gross margin went +1.8 pp — the gain came mostly from the gross line: input costs and pricing.
Net profit Net profit is what survives every cost, interest and tax — the number EPS, dividends and book value all grow from.
Healthcare Services Group, Inc. earned $0.0 B of net profit in the Mar 26 quarter, +50.0% year on year. It is the 3rd consecutive quarter of growth. Full-year FY25 profit was $0.1 B. The 4-year compound rate is 4.7%. That is 6.5% of the quarter's revenue. The same quarter a year earlier earned $0.0 B.
Mar 26 profit was $0.0 B, +50.0% year on year — the 3rd consecutive quarter of growth. On the full year, FY25 printed $0.1 B (+50.0%), and the 4-year compound rate is 4.7%.
Why profit moved: revenue contributed +2.2% and the margin +2.1 pp — the quarter was margin-led: most of the profit growth came from keeping more of each sale.
Pace comparison, last four quarters: profit +183.3% vs revenue +5.8%. Profit is growing faster than sales — fixed costs are being spread over a bigger base, and each extra dollar of revenue drops more to the bottom line.
Cash flow — the router The P&L says what was earned; the cash-flow statement says what actually arrived. Operating cash flow (CFO) against profit is the cleanest lie detector in the accounts.
Over the last 3 fiscal years 150% of Healthcare Services Group, Inc.'s reported profit arrived as operating cash — the cash follows the profit. In FY25 that was $0.1 B of operating cash against $0.1 B of profit. After $0.0 B of capital spending, $0.1 B was left as free cash.
FY25: operating cash of $0.1 B against reported profit of $0.1 B, leaving free cash of $0.1 B after $0.0 B of capital spending. Across the last 3 fiscal years the conversion rate is 150% of profit.
Cash-flow readings here are annual — that is the resolution our series carries, so this section moves once a year.
Why: conversion is measured cleanly, but the working-capital day-counts behind it sit below what we hold — the move is shown without inventing its driver.
Router verdict: the visible cash user is investment — the next section checks what the spending is buying.
Where the cash goes Working capital is the cash tied up between paying suppliers and getting paid: debtor days (customers owe), inventory days (stock waits), and the cash conversion cycle (the whole loop, in days of sales).
Healthcare Services Group, Inc. does not report the debtor, inventory and payable day-counts a cash cycle is built from, so this section reads the investment side instead. Capital spending ran $0.0 B over the last 3 years. Averaged over those years that is 0.0% of FY25 revenue a year.
Working-capital day-counts are not in our numbers for this stock, so this section reads the investment side — where the cash is being put to work.
On the investment side: capital spending of $0.0 B over the last 3 fiscal years.
The synthesis: the cash is going into capacity, not disappearing into the cycle — the question becomes whether the new capacity earns.
Return on equity Return on equity (ROE) is the profit the business earns on its shareholders’ money. With the full capital-employed split not in our numbers, ROE is the cleanest long ladder we can draw here.
Healthcare Services Group, Inc. earns a ROE of 12% in FY25. That is up from a trough of 7% in FY22. Return on invested capital clears the cost of that capital by +20.2 percentage points, so growth here adds value rather than only size. The wiring behind it is 3.3% net margin on 2.33× asset turns.
FY25 ROE is 12%, recovered from a FY22 trough of 7% — the full ladder below shows the fall and the climb, undoctored.
Why the return is what it is — the wiring (FY25): 3.3% net margin × 2.33× asset turns × 1.55× balance-sheet leverage ≈ 11.9% on equity. Margin does its share; leverage is modest — this is an earned return, not a borrowed one.
The capstone test — ROIC − WACC: 28.8% − 8.6% = a +20.2 pp spread. The 8.6% is an estimate of this company's own cost of capital — read the sign and the size of the spread, not the decimals. A spread this wide means every dollar reinvested creates more than a dollar of value — the engine compounds.
Dividend
Healthcare Services Group, Inc. pays no dividend. Across the last 12 reported quarters it has declared no dividend per share, so there is no payout history to chart and no yield to quote. Companies at this stage typically reinvest earnings rather than distribute them, which makes the cash-flow and reinvestment sections the place that cash shows up.
Healthcare Services Group, Inc. does not currently pay a dividend. Across the last 12 reported quarters the company has declared no dividend per share, so there is no payout history to chart and no yield to quote. Companies at this stage typically reinvest earnings instead of distributing them.
Debt Debt-to-equity says how much of the business is funded by borrowings. Low is the safe corner; the trend matters as much as the level.
Healthcare Services Group, Inc. carries total debt of $0.0 B against shareholder equity of $0.5 B as of Jun 26, a debt-to-equity of 0.02 — effectively unlevered. On the annual view that ratio went from 0.02 in FY21 to 0.02 in FY25. The returns elsewhere on this page are therefore earned rather than borrowed.
Jun 26: total debt of $0.0 B against shareholder equity of $0.5 B — a debt-to-equity of 0.02. On the annual view, debt-to-equity went from 0.02 (FY21) to 0.02 (FY25). The returns on this page are earned, not borrowed.
Ownership There is no quarter-by-quarter holder register to read here, so we read the crowd through short interest — the slice of tradable shares currently sold short, positioned for a fall.
3.3% of Healthcare Services Group, Inc.'s tradable float is currently sold short — some money is positioned against it. At typical trading volumes those positions would take about 3.0 days to buy back. There is no quarter-by-quarter holder register to read for this filer, so the crowd is read through short interest instead.
The latest reading: 3.3% of the float is sold short, and at typical trading volumes it would take about 3.0 days to buy those positions back. Some money is positioned against it. This is a single point-in-time reading — we do not yet hold its history, so we show no trend chart.
Why it sits there: who is doing the shorting, and why, does not travel with the number — the level is shown without inventing its story.
Safety line The Z-score estimates how far a company sits from balance-sheet distress — above roughly 3 is safe, below roughly 1.8 is the danger zone. It was built for manufacturers, so it is not applied to banks and lenders.
Healthcare Services Group, Inc.: the Z-score reads 6.49. A Z-score above roughly 3 reads as safe and below roughly 1.8 as the distress zone, so this sits well clear of distress. It is a distance-to-distress estimate from the balance sheet, not a forecast of failure.
Why it matters: a Z-score of 6.49 sits well clear of the distress zone — the balance sheet is not the risk here.
The safety line in one sentence: the Z-score reads 6.49.
| Company | Score | Price stage | Growth & earnings/35 | Capital efficiency/25 | Valuation/20 | Relative strength/20 |
|---|---|---|---|---|---|---|
| 1AMN Healthcare Services, Inc.AMN | 64.5/100Thin evidence · provisional58% evidence | LEADER | 26.0/35 Revenue 19.8% · PAT — · OPM change 6.7 pp 62% evidence | 13.2/25 ROCE 6.9% · OPM 8.5% 76% evidence | 9.2/20 P/E 30.7× · PEG — 15% evidence | 16.1/20 RS sector 15.6% · RS bench 36.1% · 1Y 92.9%12 of 12 weeks ahead 70% evidence |
| Exact sum: 26 + 13.2 + 9.2 + 16.1 = 64.5 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 2Tenet Healthcare CorporationTHC | 64.4/100Thin evidence · provisional58% evidence | TURNING | 23.7/35 Revenue — · PAT — · OPM change 6.2 pp 45% evidence | 16.5/25 ROCE 5.8% · OPM 23.2% 76% evidence | 11.1/20 P/E 7.2× · PEG — 15% evidence | 13.1/20 RS sector -5.5% · RS bench 13.7% · 1Y 53%3 of 12 weeks ahead 100% evidence |
| Exact sum: 23.7 + 16.5 + 11.1 + 13.1 = 64.4 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 3Concentra Group Holdings Parent, Inc.CON | 60.1/100Mixed-positive evidence71% evidence | BREAKING OUT | 19.8/35 Revenue 15.5% · PAT 12.9% · OPM change 0.8 pp 83% evidence | 14.8/25 ROCE 3.8% · OPM 16.8% 76% evidence | 10.2/20 P/E 15.4× · PEG — 15% evidence | 15.3/20 RS sector 0.9% · RS bench 19.9% · 1Y 43.9%9 of 12 weeks ahead 100% evidence |
| Exact sum: 19.8 + 14.8 + 10.2 + 15.3 = 60.1 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 4PACS Group, Inc.PACS | 58.7/100Thin evidence · provisional56% evidence | BREAKING OUT | 21.9/35 Revenue — · PAT — · OPM change 4.7 pp 39% evidence | 13.3/25 ROCE 5.2% · OPM 8.5% 76% evidence | 9.1/20 P/E 31.5× · PEG — 15% evidence | 14.4/20 RS sector 15% · RS bench 34% · 1Y 302.2%7 of 12 weeks ahead 100% evidence |
| Exact sum: 21.9 + 13.3 + 9.1 + 14.4 = 58.7 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 5Encompass Health CorporationEHC | 55.8/100Mixed-positive evidence81% evidence | BASING | 20.6/35 Revenue 10.1% · PAT 21% · OPM change 0.7 pp 83% evidence | 15.8/25 ROCE 4.9% · OPM 19% 76% evidence | 14.4/20 P/E 16.1× · PEG 0.68 65% evidence | 5.0/20 RS sector -25.7% · RS bench -10% · 1Y -6%1 of 12 weeks ahead 100% evidence |
| Exact sum: 20.6 + 15.8 + 14.4 + 5 = 55.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 6Chemed CorporationCHE | 55.8/100Thin evidence · provisional58% evidence | BREAKING OUT | 18.0/35 Revenue — · PAT — · OPM change -1.7 pp 45% evidence | 15.7/25 ROCE 6.6% · OPM 12.9% 76% evidence | 9.5/20 P/E 23.4× · PEG — 15% evidence | 12.6/20 RS sector -8.7% · RS bench 9.9% · 1Y 24%7 of 12 weeks ahead 100% evidence |
| Exact sum: 18 + 15.7 + 9.5 + 12.6 = 55.8 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 7Fresenius Medical Care AGFMS | 55.0/100Mixed-positive evidence81% evidence | TURNING | 21.6/35 Revenue -0.7% · PAT 43.7% · OPM change 1.5 pp 83% evidence | 11.4/25 ROCE 2.1% · OPM 11.7% 76% evidence | 15.8/20 P/E 11.9× · PEG 0.22 65% evidence | 6.2/20 RS sector -25.4% · RS bench -9.8% · 1Y -0.2%1 of 12 weeks ahead 100% evidence |
| Exact sum: 21.6 + 11.4 + 15.8 + 6.2 = 55 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 8Addus HomeCare CorporationADUS | 54.4/100Mixed-positive evidence81% evidence | BREAKING OUT | 21.2/35 Revenue 19.5% · PAT 26.6% · OPM change 0.4 pp 83% evidence | 12.3/25 ROCE 2.7% · OPM 9.4% 76% evidence | 13.7/20 P/E 17.3× · PEG 0.78 65% evidence | 7.2/20 RS sector -21.4% · RS bench -4.9% · 1Y 3.1%5 of 12 weeks ahead 100% evidence |
| Exact sum: 21.2 + 12.3 + 13.7 + 7.2 = 54.4 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 9LifeStance Health Group, Inc.LFST | 53.3/100Mixed-positive evidence64% evidence | BREAKING OUT | 22.1/35 Revenue 16.4% · PAT — · OPM change 5 pp 62% evidence | 5.8/25 ROCE 1.2% · OPM 5.5% 76% evidence | 8.5/20 P/E 106.2× · PEG — 15% evidence | 16.9/20 RS sector 10.2% · RS bench 29.9% · 1Y 134.8%9 of 12 weeks ahead 100% evidence |
| Exact sum: 22.1 + 5.8 + 8.5 + 16.9 = 53.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 10agilon health, inc.AGL | 53.2/100Mixed-positive evidence61% evidence | LEADER | 18.4/35 Revenue -2.8% · PAT — · OPM change 1.7 pp 62% evidence | 4.8/25 ROCE 1% · OPM 0.3% 76% evidence | 10.0/20 P/E — · PEG — 0% evidence | 20.0/20 RS sector 87% · RS bench 109.7% · 1Y 334%12 of 12 weeks ahead 100% evidence |
| Exact sum: 18.4 + 4.8 + 10 + 20 = 53.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 11Healthcare Services Group, Inc.this pageHCSG | 53.2/100Thin evidence · provisional52% evidence | FADING | 22.9/35 Revenue — · PAT — · OPM change 2.2 pp 45% evidence | 10.6/25 ROCE 3.6% · OPM 7.3% 76% evidence | 10.4/20 P/E 14.3× · PEG — 15% evidence | 9.3/20 RS sector -10.3% · RS bench 6.7% · 1Y 60.9%6 of 12 weeks ahead 70% evidence |
| Exact sum: 22.9 + 10.6 + 10.4 + 9.3 = 53.2 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 12DaVita Inc.DVA | 53.0/100Mixed-positive evidence81% evidence | LEADER | 16.1/35 Revenue 6.7% · PAT -6.9% · OPM change 0.5 pp 83% evidence | 13.7/25 ROCE 3.3% · OPM 14.1% 76% evidence | 8.0/20 P/E 14.3× · PEG 2.08 65% evidence | 15.2/20 RS sector 13.4% · RS bench 33.4% · 1Y 76.1%12 of 12 weeks ahead 100% evidence |
| Exact sum: 16.1 + 13.7 + 8 + 15.2 = 53 · Decision use: Price leads the evidence: RS versus the benchmark is 33.4%, but earnings trajectory is weak. Wait for revenue and profit confirmation. | ||||||
| 13Acadia Healthcare Company, Inc.ACHC | 49.1/100Thin evidence · provisional58% evidence | BREAKING OUT | 14.7/35 Revenue — · PAT — · OPM change 0.1 pp 45% evidence | 7.5/25 ROCE 1.1% · OPM 5.8% 76% evidence | 9.6/20 P/E 21.2× · PEG — 15% evidence | 17.3/20 RS sector 7.7% · RS bench 27.7% · 1Y 64.6%6 of 12 weeks ahead 100% evidence |
| Exact sum: 14.7 + 7.5 + 9.6 + 17.3 = 49.1 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 14National HealthCare CorporationNHC | 47.5/100Mixed-negative evidence81% evidence | LEADER | 16.5/35 Revenue 10.3% · PAT 16.7% · OPM change 0.2 pp 83% evidence | 10.2/25 ROCE 2.5% · OPM 8.4% 76% evidence | 9.9/20 P/E 20.3× · PEG 1.48 65% evidence | 10.9/20 RS sector 1.4% · RS bench 19.5% · 1Y 107.4%10 of 12 weeks ahead 100% evidence |
| Exact sum: 16.5 + 10.2 + 9.9 + 10.9 = 47.5 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 15Guardian Pharmacy Services, Inc.GRDN | 46.8/100Mixed-negative evidence64% evidence | TURNING | 17.2/35 Revenue 13.6% · PAT — · OPM change 1.4 pp 62% evidence | 12.6/25 ROCE 7.8% · OPM 5.3% 76% evidence | 8.7/20 P/E 45.4× · PEG — 15% evidence | 8.3/20 RS sector -6.7% · RS bench 10.7% · 1Y 103%6 of 12 weeks ahead 100% evidence |
| Exact sum: 17.2 + 12.6 + 8.7 + 8.3 = 46.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 16HCA Healthcare, Inc.HCA | 44.8/100Thin evidence · provisional58% evidence | BASING | 16.2/35 Revenue — · PAT — · OPM change -0.6 pp 45% evidence | 16.4/25 ROCE 6.9% · OPM 15% 76% evidence | 10.7/20 P/E 13.1× · PEG — 15% evidence | 1.5/20 RS sector -33.7% · RS bench -19.8% · 1Y 5%0 of 12 weeks ahead 100% evidence |
| Exact sum: 16.2 + 16.4 + 10.7 + 1.5 = 44.8 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 17The Pennant Group, Inc.PNTG | 44.7/100Mixed-negative evidence75% evidence | FADING | 20.4/35 Revenue 36.6% · PAT 20.7% · OPM change 0.1 pp 83% evidence | 9.2/25 ROCE 2.3% · OPM 6.1% 76% evidence | 4.0/20 P/E 35.9× · PEG 3.03 65% evidence | 11.1/20 RS sector -3.7% · RS bench 14.3% · 1Y 48.5%6 of 12 weeks ahead 70% evidence |
| Exact sum: 20.4 + 9.2 + 4 + 11.1 = 44.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 18Aveanna Healthcare Holdings Inc.AVAH | 44.5/100Thin evidence · provisional58% evidence | BREAKING OUT | 11.5/35 Revenue — · PAT — · OPM change -2.9 pp 45% evidence | 11.8/25 ROCE 4.8% · OPM 10.7% 76% evidence | 11.4/20 P/E 5.4× · PEG — 15% evidence | 9.8/20 RS sector -14.2% · RS bench 3.6% · 1Y 52.4%7 of 12 weeks ahead 100% evidence |
| Exact sum: 11.5 + 11.8 + 11.4 + 9.8 = 44.5 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 19Universal Health Services, Inc.UHS | 44.3/100Thin evidence · provisional58% evidence | BASING | 16.4/35 Revenue — · PAT — · OPM change 0.1 pp 45% evidence | 14.1/25 ROCE 4.1% · OPM 11.2% 76% evidence | 11.3/20 P/E 6.1× · PEG — 15% evidence | 2.5/20 RS sector -35.5% · RS bench -21.5% · 1Y -2.6%0 of 12 weeks ahead 100% evidence |
| Exact sum: 16.4 + 14.1 + 11.3 + 2.5 = 44.3 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 20Option Care Health, Inc.OPCH | 43.4/100Thin evidence · provisional58% evidence | TURNING | 17.0/35 Revenue — · PAT — · OPM change -0.5 pp 45% evidence | 11.3/25 ROCE 3.3% · OPM 5.4% 76% evidence | 10.1/20 P/E 15.8× · PEG — 15% evidence | 5.0/20 RS sector -37.2% · RS bench -23.5% · 1Y -16%2 of 12 weeks ahead 100% evidence |
| Exact sum: 17 + 11.3 + 10.1 + 5 = 43.4 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 21Pediatrix Medical Group, Inc.MD | 43.3/100Mixed-negative evidence74% evidence | FADING | 17.5/35 Revenue -2.2% · PAT — · OPM change 1.7 pp 62% evidence | 10.2/25 ROCE 2.5% · OPM 8.7% 76% evidence | 9.9/20 P/E 10.4× · PEG 1.7 65% evidence | 5.7/20 RS sector -11.9% · RS bench 5.1% · 1Y 72.4%7 of 12 weeks ahead 100% evidence |
| Exact sum: 17.5 + 10.2 + 9.9 + 5.7 = 43.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 22The Ensign Group, Inc.ENSG | 42.2/100Thin evidence · provisional58% evidence | BASING | 17.7/35 Revenue — · PAT — · OPM change 0.4 pp 45% evidence | 12.2/25 ROCE 2.7% · OPM 9% 76% evidence | 9.3/20 P/E 25.1× · PEG — 15% evidence | 3.0/20 RS sector -27.5% · RS bench -12.6% · 1Y 9.6%0 of 12 weeks ahead 100% evidence |
| Exact sum: 17.7 + 12.2 + 9.3 + 3 = 42.2 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 23Select Medical Holdings CorporationSEM | 40.7/100Mixed-negative evidence75% evidence | 11.1/35 Revenue 5.8% · PAT -20% · OPM change -1.4 pp 83% evidence | 9.7/25 ROCE 2% · OPM 6.9% 76% evidence | 13.1/20 P/E 15.4× · PEG 0.93 65% evidence | 6.8/20 RS sector -22.8% · RS bench 1.5% · 1Y 9%0 of 7 weeks ahead to 2026-07-02 70% evidence | |
| Exact sum: 11.1 + 9.7 + 13.1 + 6.8 = 40.7 · Decision use: Cheap but unconfirmed: require improving earnings before treating the valuation as an opportunity. | ||||||
| 24InnovAge Holding Corp.INNV | 39.7/100Thin evidence · provisional58% evidence | BREAKING OUT | 10.8/35 Revenue 14.2% · PAT — · OPM change -6.8 pp 62% evidence | 3.6/25 ROCE -8.8% · OPM -11.5% 76% evidence | 8.6/20 P/E 103.8× · PEG — 15% evidence | 16.7/20 RS sector 20% · RS bench 39.9% · 1Y 227.8%7 of 12 weeks ahead 70% evidence |
| Exact sum: 10.8 + 3.6 + 8.6 + 16.7 = 39.7 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 25Brookdale Senior Living Inc.BKD | 39.3/100Mixed-negative evidence61% evidence | TURNING | 17.0/35 Revenue -0.4% · PAT — · OPM change 3.2 pp 62% evidence | 5.0/25 ROCE 0.9% · OPM 6.8% 76% evidence | 10.0/20 P/E — · PEG — 0% evidence | 7.3/20 RS sector -10.3% · RS bench 6.1% · 1Y 97.4%2 of 12 weeks ahead 100% evidence |
| Exact sum: 17 + 5 + 10 + 7.3 = 39.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 26Ardent Health, Inc.ARDT | 39.2/100Mixed-negative evidence65% evidence | TURNING | 14.3/35 Revenue 6.7% · PAT -26.8% · OPM change 0.6 pp 83% evidence | 8.7/25 ROCE 1.9% · OPM 5.1% 76% evidence | 11.0/20 P/E 9× · PEG — 15% evidence | 5.2/20 RS sector -24.1% · RS bench -7.7% · 1Y -9.6%2 of 12 weeks ahead 70% evidence |
| Exact sum: 14.3 + 8.7 + 11 + 5.2 = 39.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 27Astrana Health, Inc.ASTH | 37.9/100Mixed-negative evidence81% evidence | FADING | 14.2/35 Revenue 56.8% · PAT -20.5% · OPM change -0.3 pp 83% evidence | 7.3/25 ROCE 2.2% · OPM 3% 76% evidence | 10.5/20 P/E 40.2× · PEG 1.17 65% evidence | 5.9/20 RS sector -10.4% · RS bench 6.4% · 1Y 27%10 of 12 weeks ahead 100% evidence |
| Exact sum: 14.2 + 7.3 + 10.5 + 5.9 = 37.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 28Surgery Partners, Inc.SGRY | 36.7/100Mixed-negative evidence61% evidence | FADING | 13.9/35 Revenue 5.4% · PAT — · OPM change 0.1 pp 62% evidence | 7.2/25 ROCE 0.9% · OPM 8.1% 76% evidence | 10.0/20 P/E — · PEG — 0% evidence | 5.6/20 RS sector -31% · RS bench -15.8% · 1Y -33.8%7 of 12 weeks ahead 100% evidence |
| Exact sum: 13.9 + 7.2 + 10 + 5.6 = 36.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 29Sonida Senior Living, Inc.SNDA | 34.2/100Adverse evidence64% evidence | FADING | 13.0/35 Revenue 25.5% · PAT — · OPM change -20.5 pp 62% evidence | 3.8/25 ROCE -1.9% · OPM -23.6% 76% evidence | 11.5/20 P/E 1.9× · PEG — 15% evidence | 5.9/20 RS sector -11.4% · RS bench 5.4% · 1Y 58.1%5 of 12 weeks ahead 100% evidence |
| Exact sum: 13 + 3.8 + 11.5 + 5.9 = 34.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 30COMPASS Pathways plcCMPS | 48.3/100Thin evidence · provisional47% evidence | LEADER | 19.8/35 Revenue — · PAT — · OPM change — 33% evidence | 5.0/25 ROCE -12.9% · OPM — 61% evidence | 10.0/20 P/E — · PEG — 0% evidence | 13.5/20 RS sector 18.2% · RS bench 37.9% · 1Y 168.8%12 of 12 weeks ahead 100% evidence |
| Exact sum: 19.8 + 5 + 10 + 13.5 = 48.3 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
Missing observations are not scored as bad. Their missing weight lowers confidence and pulls the final score toward neutral. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led S&P 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step curve the sector itself is placed on — basing, turning, breaking out, leader, fading, asleep — read from how many weeks running it has led S&P 500 and whether that lead is widening or shrinking. It describes where the PRICE stands, not the earnings trajectory and not a recommendation, and it is left blank for a company whose weekly history is too short or too stale to read.
Frequently asked questions
What is Healthcare Services Group, Inc.'s stock price today?
Healthcare Services Group, Inc. trades at $23.1, +77.1% over the past year. The company is valued at $2.0 B. The stock sits at 79% of its 52-week range of $15–$25, +13.9% versus its 200-day average. Against the S&P 500 it has been behind on a trailing-13-week view for 1 week. — as of 5 August 2026.
What were Healthcare Services Group, Inc.'s latest quarterly results?
Healthcare Services Group, Inc. reported revenue of $0.5 B and net profit of $0.0 B for the Mar 26 quarter. Revenue rose 2.2% and profit rose 50.0% year on year. Earnings per share were $0.37. The operating margin was 6.5%, 2.1 pp higher than a year earlier. — as of 5 August 2026.
What is Healthcare Services Group, Inc.'s revenue?
Healthcare Services Group, Inc. reported revenue of $0.5 B in the Mar 26 quarter, +2.2% year on year. For the full FY25 fiscal year, revenue was $1.8 B (+7.0%). Over the last 4 years revenue compounded at 2.9% a year. — as of 5 August 2026.
What is Healthcare Services Group, Inc.'s profit?
Healthcare Services Group, Inc. earned $0.0 B of net profit in the Mar 26 quarter, +50.0% year on year — the 3rd straight quarter of growth. Full-year FY25 profit was $0.1 B. The operating margin ran 6.5% in the latest quarter. — as of 5 August 2026.
What is Healthcare Services Group, Inc.'s market cap?
Healthcare Services Group, Inc.'s market capitalisation is $2.0 B at a stock price of $23.1. Market cap is the share price multiplied by shares outstanding, so it is restated whenever the price moves. — as of 5 August 2026.
Does Healthcare Services Group, Inc. pay a dividend?
No — Healthcare Services Group, Inc. has declared no dividend per share in any of its last 12 reported quarters, so there is no payout history and no yield to quote. That is a reading of the filed statements, not an estimate. — as of 5 August 2026.
Is Healthcare Services Group, Inc. growing?
Yes — Healthcare Services Group, Inc. is growing: latest-quarter revenue +2.2% year on year, profit +50.0%, and the margin +2.1 pp at 6.5%. The 4-year compound rates are 2.9% (revenue) and 4.7% (profit). The earnings engine currently reads: improving — as of 5 August 2026.
How is Healthcare Services Group, Inc. performing?
Healthcare Services Group, Inc.'s latest readings are below. Its latest quarter's revenue rose 2.2% and profit rose 50.0% year on year. Against the S&P 500 it has been behind on a trailing-13-week view for 1 week. This describes what the data did, not a rating. — as of 5 August 2026.
What stage is Healthcare Services Group, Inc. in?
Turning around — EPS growth swung from −22.9% at the trough to +71.4%, a 2-quarter improving streak, ROCE lifting at 9.9%. The read comes from the last 12 quarters of growth (revenue growth +5.7% latest, profit growth +75.0% latest, eps growth +71.4% latest) plus the ROCE curve, classified by deterministic rules — a trajectory read, not a buy or sell call — as of 5 August 2026.
Is Healthcare Services Group, Inc. beating the market?
Not lately — on a trailing-13-week view Healthcare Services Group, Inc. is currently behind the S&P 500 (1 week and counting; last ahead the week of 2026-07-31), the same metric the week-by-week ribbon on this page draws. Separately, on the cumulative view: over the last 1.1 years the stock moved +71% against the S&P 500's +24% — ahead of the index over the full window. — as of 5 August 2026.
Will Healthcare Services Group, Inc.'s stock price go up?
This page publishes no price forecast for Healthcare Services Group, Inc. What it measures instead: the stock price is $23.1. Direction is not something this site claims to know. — as of 5 August 2026.
Is the market betting against Healthcare Services Group, Inc.?
Somewhat — short interest is 3.3% of Healthcare Services Group, Inc.'s tradable float, about 3.0 days to cover at typical volumes. A moderate reading: some money is positioned against it. With no quarter-by-quarter holder register here, short interest is the cleanest crowd read we hold — as of 5 August 2026.
Does Healthcare Services Group, Inc. have too much debt?
No — Healthcare Services Group, Inc.'s debt-to-equity is 0.03. A year-by-year borrowings ladder is not in our numbers for this stock, so the latest reading is the cleanest hold. The returns on this page are earned, not borrowed — as of 5 August 2026.
What is Healthcare Services Group, Inc.'s capex?
Healthcare Services Group, Inc. spent $0.0 B on capital expenditure over the last 3 fiscal years, a figure derived from the change in fixed assets plus depreciation. In FY25 alone that was $0.0 B. — as of 5 August 2026.
What is Healthcare Services Group, Inc.'s cash flow?
Healthcare Services Group, Inc. generated $0.1 B of operating cash flow in FY25 and $0.1 B of free cash flow after $0.0 B of capital spending. Reported profit that year was $0.1 B, so operating cash ran ahead of profit. — as of 5 August 2026.
Is Healthcare Services Group, Inc.'s profit real cash?
Yes — over the last 3 fiscal years, 150% of Healthcare Services Group, Inc.'s reported profit arrived as operating cash. In FY25, operating cash was $0.1 B against reported profit of $0.1 B. The cash then goes mostly into building capacity. Cash-flow resolution is annual — as of 5 August 2026.
How financially safe is Healthcare Services Group, Inc.?
On the balance sheet, the Z-score reads 6.49 — above roughly 3 is safe, below roughly 1.8 is the distress zone. That sits well clear of trouble. — as of 5 August 2026.
Where is Healthcare Services Group, Inc. in its business cycle?
Healthcare Services Group, Inc.'s FY25 operating margin was 2.7%, against a 5-year band of 2.7%–3.7%: the low end of its own band, which is where recoveries start when they come. The latest quarter ran 6.5%. Profitability versus a company's own long band is the cleanest cycle clock this page holds — as of 5 August 2026.
What could break the Healthcare Services Group, Inc. story?
Biggest watch item: the price is not yet in a confirmed uptrend — timing risk, not thesis risk. Mechanically, two Friday closes in a row below the 200-day average would end the price trend — that is the exit rule this page tracks — as of 5 August 2026.
Is Healthcare Services Group, Inc. a stock worth studying right now?
This is not investment advice. The machine read: Healthcare Services Group, Inc.'s three tracks disagree. Price, valuation and the earnings engine each tell a different story — the next quarter or two settles it. The sharpest open question: the next one or two quarters of delivery. Every number on this page is drawn deterministically from the raw series, with no forecasts and no price opinions — as of 5 August 2026.